Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

Sapphire Foods India Ltd, Godawari Power & Ispat Ltd, Firstsource Solutions Ltd and National Aluminium Company Ltd are among the other gainers in the BSE's 'A' group today, 24 September 2024.Astrazeneca Pharma India Ltd soared 11.61% to Rs 7530 at 11:48 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 20901 shares were traded on the counter so far as against the average daily volumes of 934 shares in the past one month. Sapphire Foods India Ltd spiked 8.65% to Rs 382.9. The stock was the second biggest gainer in 'A' group. On the BSE, 1.22 lakh shares were traded on the counter so far as against the average daily volumes of 51731 shares in the past one month. Godawari Power & Ispat Ltd surged 7.08% to Rs 1058.6. The stock was the third biggest gainer in 'A' group. On the BSE, 1.47 lakh shares were traded on the counter so far as against the average daily volumes of 24647 shares in the past one month. Firstsource Solutions Ltd exploded 5.35% to Rs 331.7. The stock was the fourth biggest gainer in 'A' group. On the BSE, 7.64 lakh shares were traded on the counter so far as against the average daily volumes of 2.51 lakh shares in the past one month. National Aluminium Company Ltd jumped 5.16% to Rs 189.6. The stock was the fifth biggest gainer in 'A' group. On the BSE, 12.25 lakh shares were traded on the counter so far as against the average daily volumes of 5.09 lakh shares in the past one month. Powered by Capital Market - Live

Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours 4 cm and/or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. The receipt of this permission paves way for the launch of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) in India. AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The pharmaceutical firm reported net loss of Rs 11.79 crore in Q1 FY25 as compared to net profit of Rs 53.86 crore recorded in Q1 FY24. Revenue from operations jumped 31.15% year on year (YoY) to Rs 387.52 crore in the quarter ended 30 June 2024 The counter declined 1.69% to ends at Rs 6,746.45 on Monday, 23 September 2024.Powered by Capital Market - Live

Revenue from operations jumped 31.15% year on year (YoY) to Rs 387.52 crore in the quarter ended 30 June 2024, by increase in demonstrating company's focus on improving access to patients. Profit before exceptional items and tax stood at Rs 42.4 crore in first quarter of FY25, down 40.62% from Rs 71.4 crore posted in Q1 FY24. The firm reported exceptional loss of Rs 57.56 crore during the quarter. Total expenses spiked 52.25% YoY to Rs 353.47 crore in Q1 FY25. Cost of material consumed was at Rs 45.85 crore (up 140.3% YoY) while employee benefit expenses were at Rs 60.96 crore (down 10.9% YoY) during the period under review. Dr. Sanjeev Panchal, country president and managing director, AstraZeneca India, commented, 'We are pleased to report a strong financial performance this quarter. It reflects our continuous endeavour of harnessing science and commitment to bringing innovative medicines faster to India. We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programs focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers, and non-government organizations.' Bhavana Agrawal, chief finance officer, added, It's a strong start of the year with 31% revenue growth and double-digit profit margin (before exceptional item and tax). The results are an outcome of company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years. We are continuously pushing the boundaries of science and are well positioned for consistent value creation for our customers and shareholders.' AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Powered by Capital Market - Live

Net loss of Astrazeneca Pharma India reported to Rs 11.79 crore in the quarter ended June 2024 as against net profit of Rs 53.86 crore during the previous quarter ended June 2023. Sales rose 31.15% to Rs 387.52 crore in the quarter ended June 2024 as against Rs 295.47 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales387.52295.47 31 OPM %9.8222.76 - PBDT46.3175.19 -38 PBT42.4071.40 -41 NP-11.7953.86 PL Powered by Capital Market - Live

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live

Astrazeneca Pharma India announced that the Annual General Meeting (AGM) of the company will be held on 8 August 2024.Powered by Capital Market - Live